The Latest RoboSense LiDAR Perception Solution Will Support Robo Taxi Development
RoboSense today announced its launch of a developed and complete LiDAR perception solution for Robo Taxi (RS-Fusion-P5) in markets outside China. The RS-Fusion-P5 was first launched in China last month. Equipped with an RS-Ruby and four RS-BPearl, The RS-Fusion-P5 is considered to be the alternative to Waymo's LiDAR solution, further accelerating the development of Robo Taxi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005271/en/
(Graphic: Business Wire)
Full Coverage, Zero Blind Spots In The Range Of 200 Meters
RoboSense RS-Fusion-P5 uses an RS-Ruby on top of the vehicle to ensure a sensing range with a radius of more than 200 meters. However, even if the vertical field of view (FOV) of RS-Ruby reaches the perfect angles from -25° to +15°, there is still a small blind zone around the vehicle body. Therefore, to cover the small blind zone, 4 RS-BPearl embedded sideways around the vehicle form a hemisphere FOV scanning area relative to the vehicle's perspective, to guarantee a complete 360° surrounding view.
Empowers Level 4 Or Above Autonomous Vehicles With Full-stack Perception Capabilities
The RS-Fusion-P5 solution fuses point clouds from RS-Ruby and RS-BPearl in real-time, and generate laser points of more than 4,600,000pts per second.
Through its advanced AI perception algorithms, multi-sensor fusion and synchronization interfaces, vehicles are able to identify all-around obstacles and position easily and precisely.
The Main RS-Ruby With 0.1 ° Vertical Resolution, 200m @ 10% Ranging Ability
RS-Ruby achieves the anti-interference of multiple LiDAR using special laser encryption technology to filter interference signals. Meanwhile, it is not affected by the strongest direct-sunlight. Its LiDAR reflection intensity reaches a perfect balance of consistency and distinction.
RS-BPearl Reaches The Minimum Detection Range Of Less Than 5cm
The embedded four RS-BPearl form a hemispherical FOV coverage of 90 ° * 360 °, which not only can precisely identify objects around the vehicle body such as pets, children, roadbeds as well as other details of the near-field ground area, but also detect the actual height information under particular scenarios such as bridge tunnels and culverts, further supporting autonomous vehicles for driving decision making and greatly improving car safety.
The RS-Fusion-P5 is able to reach 200m detection range, 0.1° high-precision resolution with full coverage, zero blind spots in the sensing zone. It is one of the leading and developed automotive LiDAR solution for Robo Taxi available on the market. More details of RS-Fusion-P5 can be found at http://www.robosense.cn/rslidar/rs-fusion-p5.
Meanwhile, RoboSense wins CES 2020 Innovation Award for autonomous vehicle technology, and will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About RoboSense:
The world’s leading autonomous driving LiDAR perception solution provider, RoboSense, supplies LiDAR technologies to a wide range of domestic and international autonomous driving technology companies, OEMs, and tier 1 suppliers. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, ControlWorks, Aidrivers, and more. In China, RoboSense has received more than 300 million RMB in strategic investments from Alibaba’s Cainiao Network, SAIC, and BAIC, making RoboSense Asia’s number one LiDAR company, with the largest funding in China’s LiDAR industry. RoboSense has won numerous international awards, including the CES 2020 and 2019 Innovation Awards, the 2019 AutoSens Award, and the 2019 Stevie Award - Gold Award. For more information on RoboSense, see the website at http://www.robosense.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005271/en/
Contact information
Media:
Cassie Gong
RoboSense PR Manager
sqgong@robosense.cn
86-18620031448
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
